Open for recruitment
Trial summary
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
Trial details
Trial title
CAMBRIA-1
Diagnosis
Condition 3
Type of treatment
Medical Oncology
Locations